The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01574807 |
Recruitment Status :
Completed
First Posted : April 10, 2012
Results First Posted : November 17, 2020
Last Update Posted : November 17, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain | Drug: mepivacaine + lidocaine followed by lidocaine +lidocaine Drug: lidocaine + lidocaine followed by mepivacaine + lidocaine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Prospective, Randomized, Double-blind Study of the Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Inferior Alveolar Nerve Blocks. |
Study Start Date : | May 2012 |
Actual Primary Completion Date : | May 2013 |
Actual Study Completion Date : | May 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: mepivacaine + lidocaine followed by lidocaine + lidocaine
A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
|
Drug: mepivacaine + lidocaine followed by lidocaine +lidocaine
1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Other Name: Combo 1 |
Experimental: lidocaine + lidocaine followed by mepivacaine plus lidocaine
A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
|
Drug: lidocaine + lidocaine followed by mepivacaine + lidocaine
1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Other Name: Combo 2 |
- Number of Participants Achieving Pulpal Anesthesia Success. [ Time Frame: 60 minutes per injection sequence. ]An electric pulp tester will be used to test the lower jaw teeth (molars, premolars, and incisors) for anesthesia (numbness) in 4-minute time cycles for 60 minutes. Measurements of less than 80 on the EPT is considered not numb (anesthesia failure). Readings of 80 equate to anesthetic success.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- between the ages of 18 and 65 years
- good health (ASA classification I or II)
- able to provide informed consent
Exclusion Criteria:
- allergy to lidocaine or mepivacaine
- history of significant medical problem (ASA classification III or greater)
- depression
- have taken CNS depressants (including alcohol or any analgesic medications) within the last 48 hours
- lactating or pregnant
- inability to give informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01574807
United States, Ohio | |
The Ohio State University College of Dentistry, Postle Hall | |
Columbus, Ohio, United States, 43210 |
Principal Investigator: | John Nusstein, DDS, MS | Chair, Division of Endodontics |
Responsible Party: | John Nusstein, Associate Professor and Chair, Divison of Endodontics, Ohio State University |
ClinicalTrials.gov Identifier: | NCT01574807 |
Other Study ID Numbers: |
Endo-Lam2012 |
First Posted: | April 10, 2012 Key Record Dates |
Results First Posted: | November 17, 2020 |
Last Update Posted: | November 17, 2020 |
Last Verified: | November 2020 |
mepivacaine lidocaine inferior alveolar nerve block |
pulpal anesthesia mepivacaine/lidocaine lidocaine/lidocaine |
Lidocaine Mepivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents |
Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |